Babcock & Wilcox Enterprises, Inc.·4

May 19, 4:21 PM ET

Howe Alan B 4

Research Summary

AI-generated summary

Updated

Babcock & Wilcox (BW) Director Alan Howe Exercises Options, Sells Shares

What Happened

  • Alan B. Howe, a director of Babcock & Wilcox Enterprises, exercised options to acquire 85,000 shares at a strike price of $21.22 per share (total cost ≈ $1,803,700) on May 15, 2026.
  • On the same date he disposed (to the issuer) 46,750 of those shares at $21.22 per share for proceeds of $992,035; this disposition is consistent with shares being surrendered/used to satisfy tax withholding/settlement.
  • The filing also reports an award of 8,725 contingent shares (restricted stock units/derivative rights) under the company’s LTIP; these are subject to vesting conditions.

Key Details

  • Transaction date: May 15, 2026; Form 4 filed May 19, 2026 (filed within the usual two-business-day window).
  • Exercise: 85,000 shares acquired at $21.22 ($≈1,803,700).
  • Disposition to issuer (tax withholding/settlement): 46,750 shares at $21.22 (≈$992,035).
  • Grant: 8,725 contingent RSUs (no cash paid; vesting subject to plan — see footnotes).
  • Footnotes of note:
    • F1: cash settlement by the company to facilitate tax payments (withholding).
    • F3: the granted securities are contingent rights under the 2021 LTIP.
    • F4/F5: referenced vesting schedules (May 15, 2026 or 2027 or the next Annual Meeting).
    • F2: some securities are held by the Alan & Penny Howe Trust (he is a trustee).
  • Shares owned after the transaction are not specified on the provided summary; the filing indicates ownership via the Alan & Penny Howe Trust.

Context

  • This was effectively a cashless-type result of an option exercise: options were exercised and a portion of shares was surrendered/returned to the issuer to cover tax obligations (common, routine insider step).
  • The 8,725 issued as contingent RSUs are subject to vesting and do not represent immediate free trading stock.
  • The transactions are typical compensation-related activity by a director and are not, by themselves, a directional endorsement of the company’s stock.